PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21

Oncogene

Volumn 29, Issue 40, 2010, Pages 5464-5474

  Hu, F ^a   Gartenhaus, R B ^a   Eichberg, D ^a   Liu, Z ^a   Fang, H B ^a   Rapoport, A P ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

cyclin dependent kinase inhibitor p21WAF1; PBK TOPK; PDZ binding kinase; tumor suppressor p53

Indexed keywords

DOXORUBICIN; PDZ BINDING KINASE; PROTEIN P21; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PDZ-BINDING KINASE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MATURATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA BINDING MOTIF; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MICROARRAY ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TWO HYBRID SYSTEM; UPREGULATION; BIOSYNTHESIS; CELL CYCLE; CELL SEPARATION; CHROMATIN IMMUNOPRECIPITATION; DNA MICROARRAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETICS; HCT116 CELL LINE; METABOLISM; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL SEPARATION; CHROMATIN IMMUNOPRECIPITATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; IMMUNOPRECIPITATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TWO-HYBRID SYSTEM TECHNIQUES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES;

EID: 77957787506     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.275     Document Type: Article

References (42)

1. Abe Y, Matsumoto S, Kito K, Ueda N. (2000). Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J Biol Chem 275: 21525-21531.
2. Abe Y, Takeuchi T, Kagawa-Miki L, Ueda N, Shigemoto K, Yasukawa M et al. (2007). A mitotic kinase TOPK enhances Cdk1/cyclin B1-dependent phosphorylation of PRC1 and promotes cytokinesis. J Mol Biol 370: 231-245.
3. Ayllon V, O'Connor R. (2007). PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response. Oncogene 26: 3451-3461.
4. Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, Scheurich P et al. (2001). p53 upregulates cFLIP, inhibits transcription of NF-kB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 20: 571-580.
5. Brooks W, Banerjee S, Crawford DF. (2007). G2E3 is a nucleo-cytoplasmic shuttling protein with DNA damage responsive localization. Exp Cell Res 313: 665-676.
6. Brooks WS, Helton ES, Banerjee S, Venable M, Johnson L, Crawford DF et al. (2008). G2E3 is a dual function ubiquitin ligase required for early embryonic development. J Biol Chem 283: 22304-22315.
7. 2 arrest after DNA damage. Science 282: 1373-1600.
8. Cote S, Simard C, Lemieux R. (2002). Regulation of growth-related genes by interleukin-6 in murine myeloma cells. Cytokine 20: 113-120.
9. Dougherty JD, Garcia ADR, Nakano I, Livingstone M, Norris B, Polakiewicz R et al. (2005). PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase. J Neurosci 25: 10773-10785.
10. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Vogelstein B, Trent JM et al. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
11. Gaudet S, Branton D, Lue RA. (2000). Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl Acad Sci 97: 5167-5172.
12. Guo N, Krutzsch HC, Inman JK, Roberts DD. (1997). Thrombo-spondin 1 and type I repeat peptides of thromboapondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57: 1735-1742.
13. Hagn F, Klein C, Demmer O, Marchenko N, Vaseva A, Moll UM et al. (2010). BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J Biol Chem 285: 3439-3450.
14. Harada H, Nakagawa K, Saito M, Kohno S, Nagato S, Furukawa K et al. (2003). Introduction of wild-type p53 enhances thrombos-pondin-1 expression in human glioma cells. Cancer Lett 191: 109-119.
15. Herrero-Martin D, Osuna D, Ordonez JL, Sevillano V, Martins AS, Mackintosh C et al. (2009). Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signaling and reveals TOPK as a new target. Br J Cancer 101: 80-90.
16. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. (2000). Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6: 41-48.
17. Kern SE, Kinzler KW, Bruskin A, Bruskin A, Jarosz D, Friedman P et al. (1991). Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708-1711.
18. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, Ishibashi M. (1997). Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci USA 94: 11612-11616.
19. Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR et al. (1997). Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 16: 1391-1400.
20. Lee SS, Weiss RS, Javier RT. (1997). Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci USA 94: 6670-6675.
21. Li M, Zhou J, Ge Y, Matherly LH, Wu G. (2003). The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem 278: 41059-41068.
22. Matsumine A, Ogai A, Senda T, Okumura N, Satoh K, Baeg GH et al. (1996). Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein. Science 272: 1020-1023.
23. Matsumoto S, Abe Y, Fujibuchi T, Takeuchi T, Kito K, Ueda N et al. (2004). Characterization of a MAPKK-like protein kinase TOPK. Biochem Biophys Res Commun 325: 997-1004.
24. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Krammer PH et al. (1998). p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188: 2033-2045.
25. Nandi A, Tidwell M, Karp J, Rapoport AP. (2004). Protein expression of PDZ-binding kinase is strongly down-regulated during terminal differentiation of HL-60 leukemic cells. Blood Cells Mol Dis 32: 240-245.
26. Nandi AK, Ford T, Fleksher D, Neuman B, Rapoport AP. (2007). Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53. Biochem Biophys Res Commun 358: 181-188.
27. Nandi AK, Rapoport AP. (2006). Expression of PDZ-binding kinase (PBK) is regulated by cell cycle-specific transcription factors E2F and CREB/ATF. Leuk Res 30: 437-447.
28. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-1058.
29. Oh SM, Zhu F, Cho YY, Lee KW, Kang BS, Kim HG et al. (2007). T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation. Cancer Res 67: 5186-5194.
30. Park J-H, Lin M-L, Nishidate T, Nakamura Y, Katagiri T. (2006). PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 66: 9186-9195.
31. Patel S, George R, Autore F, Fraternali F, Ladbury JE, Nikolova PV. (2008). Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax. Nucleic Acids Res 36: 5139-5151.
32. Pohl U, Wagenknecht B, Naumann U, Weller M. (1999). p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis. Cell Physiol Biochem 9: 29-37.
33. Rikhof B, Corn PG, El-Deiry WS. (2003). Caspase 10 levels are increased following DNA damage in a p53-dependent manner. Cancer Biol Ther 2: 707-712.
34. Simons-Evelyn M, Bailey-Dell K, Toretsky JA, Ross DD, Fenton R, Kalvakolanu D et al. (2001). PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells. Blood Cells Mol Dis 27: 825-829.
35. L. J Biol Chem 282: 29193-29200.
36. Soussi T. (2007). p53 alterations in human cancer: more questions than answers. Oncogene 26: 2145-2156.
37. Soussi T, Asselain B, Hamroun D, Kato S, Ishioka C, Claustres M et al. (2006). Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 12: 62-69.
38. Strano S, Dell'Orso S, Di Agostino S, Fotemaggi G, Sacchi A, Blandino G. (2007). Mutant p53: an oncogenic transcription factor. Oncogene 26: 2212-2219.
39. Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein C et al. (2006). WT p53, but not tumor-derived mutants bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabi-lization. J Biol Chem 281: 8600-8606.
40. 2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells. Oncogene 25: 972-980.
41. Zhu F, Zykova TA, Kang BS, Wang Z, Ebeling MC, Abe Y et al. (2007). Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastro-enterology 133: 219-231.
42. Zykova TA, Zhu F, Lu C, Higgins LA, Tatsumi Y, Abe Y et al. (2006). Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI17951 melanoma cells. Clin Cancer Res 12: 6884-6893.